184
Results-
Press ReleaseKinnate Biopharma Inc. Sells Its Investigational Pan-RAF Inhibitor, Exarafenib, to Pierre Fabre LaboratoriesCreated on : - Last modified on :• Kinnate has entered into an Asset Purchase Agreement (the “APA”) with Pierre Fabre Laboratories for global rights to exarafenib and other pan-RAF program assets.• The transaction is in furtherance of Kinnate’s previously announced pursuit of strategic alternatives.
-
Our Sustainable Development PolicyCreated on : - Last modified on :
Being environmentally-friendly, reducing our carbon footprint and supporting our communities, while delivering safe and effective products
-
Acting in Full Transparency with the Green Impact Index ConsortiumCreated on : - Last modified on :
The labeling tool that gives you a clear picture of the environmental and social impacts of our products, based on an easy-to-understand score: A+B+C+D+E.
-
Build Your CareerCreated on : - Last modified on :
Growing in an international, forward-thinking company
-
Privacy policy and cookies policyCreated on : - Last modified on :Privacy policy and cookies policy Thank you for visiting Our Website. Ensuring data protection and data security for our customers and users is a top priority for us at Pierre Fabre. This privacy policy explains what data is collected when you visit and use our website and how they are processed.
-
Job offersCreated on : - Last modified on :
-
2023 Annual report of Pierre Fabre groupCreated on : - Last modified on :
-
NewsroomCreated on : - Last modified on :
-
Visit Our PremisesCreated on : - Last modified on :
-
TalentCreated on : - Last modified on :
We take care of life by designing and developing innovative solutions inspired by consumers and patients, and contributing to the well-being of everyone from health to beauty.